<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public">
	<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>112th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 960</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20110512">May 12, 2011</action-date>
			<action-desc><sponsor name-id="S173">Mr. Kerry</sponsor> (for himself,
			 <cosponsor name-id="S289">Mr. Alexander</cosponsor>, and
			 <cosponsor name-id="S247">Mr. Wyden</cosponsor>) introduced the following bill;
			 which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To provide for a study on issues relating to access to
		  intravenous immune globulin (IVIG) for Medicare beneficiaries in all care
		  settings and a demonstration project to examine the benefits of providing
		  coverage and payment for items and services necessary to administer IVIG in the
		  home.</official-title>
	</form>
	<legis-body>
		<section id="id02C1F9E6BCD34C40B401FBDF5E860C0A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Medicare IVIG Access
			 Act</short-title></quote>.</text>
		</section><section id="id08C4D08B927E43A09F600ED298CF2D33"><enum>2.</enum><header>Medicare patient
			 IVIG access demonstration project</header>
			<subsection id="id7DC15945A9614EC5940E989F5E04A239"><enum>(a)</enum><header>Establishment</header><text>The
			 Secretary shall establish and implement a demonstration project under title
			 XVIII of the Social Security Act to evaluate the benefits of providing payment
			 for items and services needed for the administration, within the homes of
			 Medicare beneficiaries, of intravenous immune globin for the treatment of
			 primary immune deficiency diseases.</text>
			</subsection><subsection id="id625EBFDF6BF54D24B7BEDF5069EA1BB0"><enum>(b)</enum><header>Duration and
			 scope</header>
				<paragraph id="id97A76273A0E64958BA5B688E8F6A263D"><enum>(1)</enum><header>Duration</header><text>Beginning
			 not later than 6 months after the date of enactment of this Act, the Secretary
			 shall conduct the demonstration project for a period of 3 years.</text>
				</paragraph><paragraph id="id7477BC37D6824F778D05D432DE6CFCA1"><enum>(2)</enum><header>Scope</header><text>The
			 Secretary shall enroll not greater than 4,000 Medicare beneficiaries who have
			 been diagnosed with primary immunodeficiency disease for participation in the
			 demonstration project. A Medicare beneficiary may participate in the
			 demonstration project on a voluntary basis and may terminate participation at
			 any time.</text>
				</paragraph></subsection><subsection id="idC7CE3225F39945B9B3D003C0E5AD8669"><enum>(c)</enum><header>Reimbursement</header><text>The
			 Secretary shall establish an hourly rate for payment for items and services
			 needed for the administration of intravenous immune globin based on the
			 low-utilization payment adjustment under the prospective payment system for
			 home health services established under section 1895 of the Social Security Act
			 (42 U.S.C. 1395fff).</text>
			</subsection><subsection id="id4E52B42B3B1B483FBD43123D51697DA0"><enum>(d)</enum><header>Study and
			 report to Congress</header>
				<paragraph id="id56340C71159B4262884D274E7BFD5C5B"><enum>(1)</enum><header>Interim
			 evaluation and report</header><text>Not later than 24 months after the date of
			 enactment of this Act, the Secretary shall submit to Congress a report that
			 contains the following:</text>
					<subparagraph id="id1E6C70841D7243EDB362F079071C9C1C"><enum>(A)</enum><text>An interim
			 evaluation of the impact of the demonstration project on access for Medicare
			 beneficiaries to items and services needed for the administration of
			 intravenous immune globin within the home.</text>
					</subparagraph><subparagraph id="id946F47EB664447789CA668B9F837CE6C"><enum>(B)</enum><text>An analysis of
			 the appropriateness of implementing a new methodology for payment for
			 intravenous immune globulins in all care settings under part B of title XVIII
			 of the Social Security Act (42 U.S.C. 1395k et seq.).</text>
					</subparagraph><subparagraph id="idDAE281E0224940A6A2C5D10C7B1C72C2"><enum>(C)</enum><text>An analysis of
			 the feasibility of reducing the lag time with respect to data used to determine
			 the average sales price under section 1847A of the Social Security Act (42
			 U.S.C. 1395w–3a).</text>
					</subparagraph><subparagraph id="id90747159E86949DDA003CB09B4E88338"><enum>(D)</enum><text>An update to the
			 report entitled “Analysis of Supply, Distribution, Demand, and Access Issues
			 Associated with Immune Globulin Intravenous (IGIV)”, issued in February 2007 by
			 the Office of the Assistant Secretary for Planning and Evaluation of the
			 Department of Health and Human Services.</text>
					</subparagraph></paragraph><paragraph id="id7D6D7D2DA5C4418383A65423A2C92777"><enum>(2)</enum><header>Final
			 evaluation and report</header><text>Not later than July 1, 2015, the Secretary
			 shall submit to Congress a report that contains a final evaluation of the
			 impact of the demonstration project on access for Medicare beneficiaries to
			 items and services needed for the administration of intravenous immune globin
			 within the home.</text>
				</paragraph></subsection><subsection id="id6887760E2A2C4B669645A3C08A77D083"><enum>(e)</enum><header>Offset</header>
				<paragraph id="id2A22E2219B7D4EC8AA9FF3AA0D3E8873"><enum>(1)</enum><header>In
			 general</header><text>Section 1861(n) of the Social Security Act (42 U.S.C.
			 1395x(n)) is amended by adding at the end the following: “Such term includes
			 disposable drug delivery systems, including elastomeric infusion pumps, for the
			 treatment of colorectal cancer.”.</text>
				</paragraph><paragraph id="idF1E36C6194E94A1AAF342C1C1E5F2032"><enum>(2)</enum><header>Effective
			 date</header><text>The amendment made by paragraph (1) shall apply to items
			 furnished on or after the date of enactment of this Act.</text>
				</paragraph></subsection><subsection id="id96BBE230068A4660AB640769D92C32E2"><enum>(f)</enum><header>Definitions</header><text>In
			 this Act:</text>
				<paragraph id="id0A83EC8DEB964605B9A60DC5DE02A5CB"><enum>(1)</enum><header>Demonstration
			 project</header><text>The term <term>demonstration project</term> means the
			 demonstration project conducted under this Act.</text>
				</paragraph><paragraph id="idE2DF012EB8064424928989436CCB326A"><enum>(2)</enum><header>Medicare
			 beneficiary</header><text>The term <term>Medicare beneficiary</term> means an
			 individual who is entitled to, or enrolled for, benefits under part A of title
			 XVIII of the Social Security Act or enrolled for benefits under part B of such
			 title.</text>
				</paragraph><paragraph id="idCE3E91EF78764EE99C54E237E471C461"><enum>(3)</enum><header>Secretary</header><text>The
			 term <term>Secretary</term> means the Secretary of Health and Human
			 Services.</text>
				</paragraph></subsection></section></legis-body>
</bill>
